| 발표일자: |
2018년 11월 2일(금) ~ 11월 4(일) |
| 발표번호: |
P(e-poster)-146 |
| 발표장소: |
코엑스 컨퍼런스룸 3층 301 A-B |
|
|
| 결절맥락막혈관병증과 전형 신생혈관성 연령관련황반변성의 10년 추적관찰 결과 |
| 서울대학교 의과대학 안과학교실(1)
분당서울대병원 안과 (2) |
| 박영주(1,2), 조관혁(2), 우세준(1,2), 박규형(1,2) |
|
목적 : To compare clinical characteristics and long-term visual outcome of patients with polypoidal choroidal vasculopathy (PCV) and typical neovascular age-related macular degeneration (nAMD) in the real-world setting.
방법 : The medical records of patients diagnosed with nAMD including PCV at Seoul National University Bundang Hospital were reviewed retrospectively. Basic clinical characteristics including age, sex, and underlying diseases and annual changes in best-corrected visual acuity(BCVA) were collected.
결과 : 193 eyes of 177 patients with PCV and 596 eyes of 518 patients with typical nAMD were included. Mean follow-up period of total patients was 4.05±2.67 year. In both PCV and typical nAMD group, treatment strategy had changed from 'PDT' to 'anti-VEGF injection' or 'PDT combined with anti-VEGF injection' since 2006. Onset age were younger in the PCV group than in the typical nAMD group (67.4 ±7.9 vs 71.9±8.1, p<.001). BCVA was better in the PCV group than the typical nAMD group at the initial visit (0.56±0.51 vs 0.78±0.60, P<.001) and at the final visit (0.69±0.71 vs 1.01±0.76, P<.001).
결론 : Long-term visual acuity gradually deteriorated in both the PCV and typical nAMD group in the real-world, but the PCV group showed better visual outcome than the nvAMD group. The change of treatment strategy from PDT to anti-VEGF injections improved the visual outcome in both groups.
|
| |